MindRank to Showcase AI-Driven Drug Discovery Platform and Clinical Pipeline at BIO International Convention 2025

From June 16 to 19, 2025, the world's largest biotechnology industry event — BIO International Convention 2025 — will be held in"United States, Boston"Hold."MindRank"Will attend this conference to discuss the integration and innovation of AI technology and biomedicine with top global scientists, pharmaceutical executives, and representatives of investment institutions, exploring new opportunities for AI-driven drug discovery collaborations.

The BIO International Convention, founded in 1993 by the Biotechnology Innovation Organization (BIO), has becomeOne of the largest, most professional, and most influential biotechnology annual events globally.The BIO Convention attracts approximately 20,000 global biotechnology professionals each year, bringing together leading pharmaceutical companies, biotech firms, investors, and service providers in the industry. Through a series of professional forums, matchmaking sessions, and other activities, it provides participants with a comprehensive platform for information exchange and release, technical cooperation and transactions, as well as venture capital financing.

As a representative enterprise in the AI pharmaceuticals field, "MindRank" is committed to empowering innovative drug research and development with a world-leading AI pharmaceuticals platform, accelerating the availability of better drugs for the public. Currently, inMolecule Pro™Driven by a core industrial-grade one-stop AI pharmaceutical platform, the companyThe first self-developed GLP-1RA small molecule oral drug MDR-001 has completed Phase IIb clinical research, and the new anti-tumor drug MRANK-106 has received clinical approval from the U.S. FDA.In addition, the company has several potential best-in-class or first-in-class projects in the fields of metabolism and oncology at the IND-Enabling stage.

At the same time, relying on cutting-edge AI large model technology, MindRank has expanded its technical platform fromSmall Molecule DrugsExtended toLarge Molecule Antibodies and Antibody-Drug ConjugatesField, related technologies have been fully validated in multiple internal pipelines and collaboration projects with listed pharmaceutical companies. If you would like to learn more about the company's technological breakthroughs or pipeline progress, please feel free to contact us via the BIO Partnering™ platform or email bd@mindrank.ai, and together we can embark on a new chapter of AI-powered drug discovery.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby enabling more diseases to be treatable and allowing more lives to regain health.

The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamics simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™. The company’s AI pharmaceutical solutions were recognized by the authoritative European and American institution Deep Pharma Intelligence as one of “the 11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020.” In 2023, it was included in Forbes’ “Forbes Asia 100 to Watch” list, with only 11 startups from mainland China making the list. In 2024, it was named one of “China’s Most Socially Impactful Startups” on Fortune magazine’s IMPACT list.

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai